Main Article Content
Polypharmacy has been implicated in adverse drug events, excessive healthcare spending, and complications in the management of COVID-19. Multimorbid older adults suffer some of the most severe COVID-19 health outcomes and are at the highest risk of polypharmacy. This article aims to highlight the issue of polypharmacy in the context of the current pandemic and suggests several interventions to minimize the disruption of effective care for at-risk populations. Such interventions include coordinating care delivery, changing physician prescribing attitudes, and improving patient health literacy. Polypharmacy is a major contributor to the risk of adverse drug events before, during, and after COVID-19 treatment. Managing polypharmacy is therefore critical to the provision of patient care during the pandemic.